Answers are grounded in this paper and cite their sources.
Circulating tumor DNA (ctDNA) assays are commonly described by fixed variant allele fraction (VAF)-based limits of detection. However, such metrics overlook a fundamental constraint: the finite number of analyzable DNA molecules in an individual plasma sample. As a result, nominal assay sensitivity may overestimate what is physically achievable in routine clinical specimens. Genome-equivalent (GE) distributions from three independent liquid-biopsy cohorts comprising 5238 plasma samples were integrated with a Poisson-based sampling model to estimate input-limited detectability for single-locus variants. For each sample, the lower limit of detection was defined as the minimum VAF associated with a 95% probability of observing at least 1, 3, 5, or 10 mutant molecules. GE input varied widely (median 5531; interquartile range 2784-13,060). Detection at 1% VAF was theoretically achievable for nearly all samples, but performance declined sharply at lower VAFs and with increasing evidentiary thresholds. At 0.1% VAF, 72% of samples supported detection of at least one mutant molecule, compared with 46%, 35%, and 21% for thresholds of at least 3, 5, and 10 molecules. At 0.01% VAF, fewer than 10% of samples met any detection criterion. These findings indicate that many clinical plasma samples are unlikely to support reliable single-locus detection at very low VAFs, independent of assay design. Sample-aware interpretation of ctDNA results that accounts for molecular input is therefore warranted.
No takes yet. Share an insight, caveat, or question.
Alexander Gamisch (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: